Enhanced oral bioavailability of paclitaxel by coadministration of the p-glycoprotein inhibitor KR30031

Pharmaceutical Research

Volumn 20, Issue 1, 2003, Pages 24-30

  Woo, Jong Soo ^a,b   Lee, Chang Hyun ^b   Shim, Chang Koo ^c   Hwang, Sung Joo ^a  

^a Chungnam National University   (South Korea)

^b Hanmi Pharmaceutical Co Ltd   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

CYP3A inhibitor; KR 30031; P glycoprotein inhibitor; P glycoprotein mediated efflux pump; Paclitaxel; Poor oral bioavailability

Indexed keywords

KETOCONAZOLE; KR 30031; PACLITAXEL; UNCLASSIFIED DRUG; VERAPAMIL DERIVATIVE;

ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG STRUCTURE; DRUG TRANSPORT; ENZYME MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TRANSPORT KINETICS;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; HUMANS; MALE; P-GLYCOPROTEIN; PACLITAXEL; RATS; RATS, SPRAGUE-DAWLEY; VERAPAMIL;

EID: 0037261361     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022286422439     Document Type: Article

References (24)

1. A. E. Mathew, M. R. Mejillano, J. P. Nath, R. H. Himes, and V. J. Stella. Synthesis and evaluation of some water-soluble pro-drugs and derivatives of taxol with antitumor activity. J. Med. Chem. 35:145-151 (1992).
2. H. M. Schellens. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents. WO Patent 99-12570 (1999).
3. R. B. Weiss, R. C. Donehower, P. H. Wiemik, T. Ohnuma, R. J. Gralla, D. L. Trump, J. R. Baker, D. A. VanEcho, D. D. Von-Hoff, and B. Leyland-Jones. Hypersensitivity reactions from taxol. J. Clin. Oncol. 8:1263-1268 (1990).
4. E.K. Rowinsky, E.A. Eisenhauer, V. Chaudhry, S.G. Arbuck, and R.C. Donehower. Clinical toxicities encountered with paclitaxel (Taxol®). Semin. Oncol. 20(suppl. 3):1-15 (1993).
5. M. Suffness. TAXOL® Science and Applications, CRC Press, Florida, 1995.
6. D. S. Sonnichsen and M. V. Relling. Clinical pharmacokinetics of paclitaxel. Clin. Pharmacokinet. 27:256-269 (1994).
7. J. L. Eiseman, N. D. Eddington, J. Leslie, C. MacAuley, D. L. Sentz, M. Zuhowski, J. M. Kujawa, D. Young, and M. J. Egorin. Plasma pharmacokinetics and tissue distribution of paclitaxel in DC2F1 mice. Cancer Chemother. Pharmacol. 24:465-471 (1994).
8. B. Monsarrat, E. Mariel, S. Cros, M. Gares, D. Guenard, F. G. Voegelein, and M. Wright. Taxol metabolism. Isolation and identification of three major metabolites of taxol in rat bile. Drug Metab. Dispos. 18:895-901 (1990).
9. U. K. Walle and T. Walle. Taxol transport by human intestinal epithelial Caco-2 cells. Drug Metab. Dispos. 26:343-346 (1998).
10. A. Sparreboom, J. Asperen, U. Mayer, A. H. Schinkel, J. W. Stair, D. K. F. Meijer, P. Borst, W. J. Nooijen, J. H. Beijnen, and O. Tellingen. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA 94:2031-2035 (1997).
11. G. A. Fisher and B. I. Sikic. Clinical studies with modulators of multidrug resistance. Drug Resist. Clin. Oncol. Hematol. 9:363-382 (1995).
12. E. Hofsli and J. N. Meyer. Reversal of multidrug resistance by lipophilic drugs. Cancer Res. 50:3997-4002 (1990).
13. L. J. Bain, J. B. McLachlan, and G. A. LeBlanc. Structure-activinty relationship for xenobiotic transport substrates and inhibitory ligands of P-glycoprotein. Environ. Health Perspect. 105:812-818 (1997).
14. M. M. Gottesman and I Pastan. Clinical trials of agents that reverse multidrug resistance. J. Clin. Oncol. 7:409-411 (1989).
15. R. F. Ozols, R. E. Cunnion, R. W. Klecker, T. C. Hamilton, Y. Ostchega, J. E. Parrillo, and R. C. Young. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J. Clin. Oncol. 5:641-647 (1987).
16. S. U. Choi, B. H. Lee, K. H. Kim, E. J. Choi, S. H. Park, H. S. Shin, S. E. Yoo, N. P. Jung, and C. O. Lee. Novel multidrug-resistance modulators, KR-30031 and KR-30031, in cancer cells. Anticancer Res. 17:4577-4582 (1997).
17. J. Asperen, A. Sparreboom, A. H. Schinkel, P. Borst, W. J. Nooijen, and J. H. Beijnen. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br. J. Cancer 76:1181-1183 (1997).
18. V. J. Wacher, L. Salphati, and L. Z. Benet. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv. Drug Deliv. Rev. 20:99-112 (1996).
19. L. Z. Benet, C. Y. Wu, M. F. Hebert, and V. J. Wacher. Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery. J. Control. Release 39:139-143 (1996).
20. P. F. Augustijns, T. P. Bradshaw, L. S. Gan, R. W. Hendren, and D. R. Thakker. Evidence for a polarized efflux system in Caco-2 cells capable of modulating cyclosporin A transport. Biochem. Biophys. Res. Commun. 197:360-365 (1993).
21. K. I. Kwon. Effect of caffeine on ceftriaxone disposition (Physiological pharmacokinetic model of ceftriaxone and tenoxicam). Ph.D. thesis, University of Queensland, Australia (1987).
22. D. Y. Gomez, V. J. Wacher, S. J. Tomlanovich, M. F. Hebert, and L. Z. Benet. The effect of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin. Pharmacol. Ther. 58:15-19 (1995).
23. 3H]taxol in the Sprague-Dawley rat. Drug Metab. Dispos. 22:254-258 (1994).
24. C. Y. Wu, L. Z. Benet, M. F. Hebert, S. K. Gupta, M. Rowland, D. Y. Gomez, and V. J. Wacher. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine. Clin. Pharmacol. Ther. 58:492-497 (1995).